VIVUS Names New CEO and Chairman

The recent turmoil at the upper ranks of VIVUS (NASDAQ: VVUS  ) seems to be abating. The company announced that it has appointed a replacement CEO and a new board chairman. Occupying the former position is Anthony Zook, who takes the reins from the recently ousted Leland Wilson. Meanwhile, Michael Astrue has been tapped to be the company's chairman. Both appointments are effective immediately.

Before being named VIVUS' CEO, Zook was executive vice president of global commercial operations for AstraZeneca. He also served as president of Medimmune, now an AstraZeneca subsidiary.

Astrue was previously the commissioner of Social Security and chairman of the Massachusetts Biotechnology Council. In the private sector he worked as CEO of Transkaryotic Therapies, which Shire acquired in 2005.

The new chairman was direct about his and Zook's mission. In the press release announcing the two appointments, VIVUS quoted Astrue as saying that "we intend to move quickly on our four main goals: (1) expand use of Qsymia through targeted patient and physician education, (2) find the right partner for Qsymia, (3) quickly create a pathway for approval in Europe, and (4) eliminate expenses that are not essential to expanding use of Qsymia."

Qsymia is a medication the company developed to combat obesity.

Read/Post Comments (0) | Recommend This Article (0)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

Be the first one to comment on this article.

Compare Brokers

Fool Disclosure

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 2553073, ~/Articles/ArticleHandler.aspx, 9/27/2016 4:54:12 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...

Today's Market

updated 7 hours ago Sponsored by:
DOW 18,094.83 -166.62 -0.91%
S&P 500 2,146.10 -18.59 -0.86%
NASD 5,257.49 -48.26 -0.91%

Create My Watchlist

Go to My Watchlist

You don't seem to be following any stocks yet!

Better investing starts with a watchlist. Now you can create a personalized watchlist and get immediate access to the personalized information you need to make successful investing decisions.

Data delayed up to 5 minutes

Related Tickers

9/26/2016 4:00 PM
VVUS $1.24 Up +0.11 +9.73%
VIVUS CAPS Rating: **